Clinical Roundup Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC June 26, 2026Vol.52 No.25
Clinical Roundup Mezigdomide + carfilzomib + dexamethasone regimen reduces disease progression in r/r MM, phase III trial finds June 26, 2026Vol.52 No.25
Clinical Roundup Researchers at Rutgers Cancer Institute and Rutgers Business School build simulation method to reduce cancer treatment times June 26, 2026Vol.52 No.25
Clinical Roundup TAMP procedure shows 52% reduction in pancreatic tumor metabolic activity, Moffitt case study shows June 26, 2026Vol.52 No.25
Clinical Roundup Sylvester researchers discover method of disrupting inflammatory network that helps pancreatic cancer resist treatment June 26, 2026Vol.52 No.25
Clinical Roundup Neutrophils help triple-negative breast cancer cells spread to other organs, BCM study finds June 26, 2026Vol.52 No.25
Clinical Roundup GABA boosts cancer-protecting immune cells in females with glioblastoma, preclinical study finds June 26, 2026Vol.52 No.25
Clinical Roundup All-oral regimen of decitabine-cedazuridine + venetoclax yields 47% complete response rate, ASCERTAIN-V phase I/II clinical trial finds June 18, 2026Vol.52 No.24
Clinical Roundup Talvey + Darzalez Faspro shows significant survival gains in r/r MM, phase III MonumenTAL-3 study finds June 18, 2026Vol.52 No.24
Clinical Roundup Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds June 18, 2026Vol.52 No.24
